Authorised Therapeutic use (Phase IV) osteoporosis

ALEXIS

EU CTIS ID: 2023-510042-24-01

What this study is testing

to investigate the effect on fracture risk of discontinuing alendronate in a randomized controlled study

  • Therapeutic use (Phase IV)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • Female, Postmenopausal, Current treatment with Alendronate, Alendronate treatment >3 år AND no previous major osteoporotic fracture OR Alendronate treatment >5 år AND latest major osteporotic fracture > 3 years ago, ** Major osteoprotic fracture is defined as low energy fractures in hip, proximal humerus, distal radius, or vertebral fracture

You likely can't join if

  • T-score < - 3,5 in hip (total hip or femoral neck) or lumbar spine, Treatment with systemic glucocorticoids for more than two weeks, ongoing or within 12 months, Uncontrolled inflammatory disease, Active malignancy, eGFR < 40 mL/min, Atypical femur fracture (ever), OsteoNecrosis of the Jaw (active), Unable to give inform consent

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling female, 18-64 years, 65+ years. The study team makes the final eligibility decision.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.